Retatrutide for Beginners: The Complete Step-by-Step Start Guide
If you have just obtained retatrutide, or are about to, and you have never handled an injectable peptide before, this is your one-page starting point. It walks through what retatrutide is, the supplies you need, how to mix and draw it, how to inject, a cautious first 12 weeks, the side effects to watch for, and what results actually look like over time.
One thing has to be clear up front. Retatrutide is investigational. It is not approved by the U.S. Food and Drug Administration (FDA) for any use, and no licensed, quality-controlled retatrutide product exists for patients. The vials sold online as compounded or research material are not FDA-reviewed for identity, purity, sterility, or dose accuracy, and the FDA has specifically warned about unapproved GLP-1 class drugs used this way (FDA). This guide is education, not medical advice or instruction to self-treat. Every procedural and dosing detail below should be reviewed with a licensed clinician before you act on it.
What retatrutide is and how the triple agonist works
Retatrutide is an experimental once-weekly injectable peptide being developed by Eli Lilly for obesity and related conditions. In plain English, it is a "triple agonist," meaning it switches on three different gut and metabolic hormone receptors at the same time: the GLP-1 receptor, the GIP receptor, and the glucagon receptor (Jastreboff et al., NEJM 2023).
Here is what each pathway broadly does. GLP-1 and GIP are incretin hormones that increase a feeling of fullness, slow how fast the stomach empties, and improve how the body handles blood sugar. The glucagon receptor is the newer addition; activating it is thought to increase energy expenditure and support fat metabolism in the liver. Combining all three is what separates retatrutide from single-target drugs like semaglutide (GLP-1 only) and dual-target tirzepatide (GLP-1 plus GIP). For a deeper plain-language explainer, see our what is retatrutide guide.
In the Phase 2 trial, 338 adults with obesity received 1, 4, 8, or 12 mg once weekly, or placebo, for 48 weeks. At the highest 12 mg dose, average body weight fell about 17.5% by week 24 and about 24.2% by week 48, versus roughly 1.6% and 2.1% on placebo (Jastreboff et al., NEJM 2023). Those are striking numbers, but they come from one mid-stage study. Larger Phase 3 trials are still ongoing, and long-term safety is not yet established.
Before you start: who should and should not use it
Because there is no approved retatrutide label, the safest reference points are the warnings on closely related, approved incretin drugs, plus plain common sense. Treat the following as reasons to stop and talk to a clinician, not as a checklist you clear on your own.
The approved drugs in this class carry a boxed warning against use in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), based on thyroid tumors seen in rodents (FDA Zepbound label). That same caution is reasonable for retatrutide. Other situations where this class is generally avoided or used only under close supervision include a history of pancreatitis, severe gastrointestinal disease such as gastroparesis, gallbladder disease, type 1 diabetes, and any history of serious hypersensitivity to incretin drugs (DailyMed: Zepbound).
You should not use retatrutide if you are pregnant, trying to become pregnant, or breastfeeding. The class is not recommended in pregnancy, and rapid weight loss plus reduced food intake can be unsafe for a developing baby (DailyMed: Zepbound). If you take insulin or a sulfonylurea, the combination raises the risk of low blood sugar and needs a clinician's dose adjustment (FDA Zepbound label).
A sensible pre-start screen, done with a clinician, usually includes a review of your personal and family medical history, baseline labs (such as blood glucose or HbA1c, kidney and liver function), and a conversation about every medication and supplement you take. None of that can be replaced by a guide on the internet.
Your beginner supply checklist
You cannot inject retatrutide straight from the vial. It typically arrives as a freeze-dried (lyophilized) powder that must be reconstituted with sterile liquid first. Here is the basic kit a beginner gathers.
| Item | What it is for | Beginner notes |
|---|---|---|
| Retatrutide vial | The lyophilized peptide | Common research vial sizes are 5 mg, 10 mg, 15 mg, and 20 mg |
| Bacteriostatic water | The liquid that dissolves the powder | The 0.9% benzyl alcohol version is preferred for multi-dose vials |
| Reconstitution syringe (3 mL) | Adds water to the vial | A larger syringe makes adding water easier |
| Insulin syringes (U-100, 29 to 31 gauge, 5/16 inch) | Drawing and injecting your dose | U-100 means 100 units per mL; the small needle is for under-the-skin shots |
| Alcohol swabs | Cleaning vial tops and skin | Use a fresh swab every time |
| Sharps container | Safe needle disposal | A rigid puncture-proof container, never the household trash |
Buy more syringes than you think you need, since each one is single-use. Keep everything in a clean, dry area away from children and pets.
How to reconstitute your first vial
Reconstitution simply means adding the right amount of bacteriostatic water to the powder so it becomes a liquid you can measure. The amount of water you choose sets the concentration, which then determines how many units equal each milligram. This is the step beginners most often get wrong, so go slowly and double-check the math. A common, easy-to-measure approach is to use enough water that 1 mg ends up equal to a round number of units.
| Vial size | Bacteriostatic water added | Resulting concentration | What 1 mg equals |
|---|---|---|---|
| 5 mg | 1 mL | 5 mg/mL | 20 units |
| 10 mg | 1 mL | 10 mg/mL | 10 units |
| 10 mg | 2 mL | 5 mg/mL | 20 units |
| 15 mg | 1.5 mL | 10 mg/mL | 10 units |
| 20 mg | 2 mL | 10 mg/mL | 10 units |
The general steps: swab both vial tops, draw your chosen volume of bacteriostatic water into the larger syringe, and inject it slowly down the inside wall of the retatrutide vial so the stream does not blast the powder. Do not shake. Swirl gently and let it sit a minute or two until the solution is clear. These figures are illustrative examples of the math, not a prescription. For full instructions, the exact mixing tables, and pictures, follow our complete how to reconstitute retatrutide guide and the matching reconstitution and dosage chart.
Reading your dose in units
Insulin syringes are marked in units, not milligrams, so you need one quick conversion. The formula is:
units to draw = (dose in mg / concentration in mg per mL) x 100
The easier way to think about it: once you know "what 1 mg equals" from your reconstitution table above, you just multiply. If your vial is mixed so 1 mg equals 10 units, then a 2 mg dose is 20 units, and a 0.5 mg dose is 5 units. If 1 mg equals 20 units, a 2 mg dose is 40 units.
| Concentration | 0.5 mg dose | 1 mg | 2 mg | 4 mg |
|---|---|---|---|---|
| 5 mg/mL (1 mg = 20 units) | 10 units | 20 units | 40 units | 80 units |
| 10 mg/mL (1 mg = 10 units) | 5 units | 10 units | 20 units | 40 units |
Write your specific concentration and unit conversions on a card and keep it with your supplies so you are never doing mental math at injection time. Our retatrutide dosage page walks through these calculations in more detail.
How to inject retatrutide
Retatrutide, like other drugs in its class, is given as a subcutaneous injection, meaning into the fat layer just under the skin, not into muscle or a vein. The usual sites are the abdomen (staying at least two inches away from the navel), the front of the thighs, and the back of the upper arms.
A simple first-timer sequence looks like this: wash your hands, swab the chosen site and let it dry, draw your dose into a fresh insulin syringe and tap out air bubbles, gently pinch a fold of skin, insert the needle at the angle your clinician recommends (often 45 to 90 degrees), push the plunger steadily, then withdraw and dispose of the needle in your sharps container. Many people feel little more than a pinprick.
Two beginner habits matter. First, rotate sites every week so you do not develop hard or lumpy spots from injecting the same place repeatedly. Second, never reuse a needle. For the full technique, including how to handle bleeding, what a good injection looks like, and a rotation chart, see our detailed how to inject retatrutide guide.
Your first 12 weeks: a conservative beginner titration
The single most important rule for tolerating any incretin drug is start low and go slow. In the Phase 2 trial, the worst gastrointestinal side effects were clearly dose-related, and simply starting at 2 mg instead of 4 mg reduced them (Jastreboff et al., NEJM 2023). The approved drugs in this class follow the same philosophy with a low starting dose held for at least four weeks before any increase (FDA Zepbound label).
The schedule below is an illustrative, conservative example, not a recommendation or a prescription. The right starting point and pace for any individual must be set with a clinician.
| Weeks | Illustrative weekly dose | Notes |
|---|---|---|
| 1 to 4 | 1 mg to 2 mg | Lowest comfortable start; let your gut adapt fully |
| 5 to 8 | 2 mg to 4 mg | Only increase if the prior dose was well tolerated |
| 9 to 12 | 4 mg | Hold here; do not chase a higher dose early |
Notice this stays well below the 8 mg and 12 mg doses studied in the trial. Beginners do not need high doses to start seeing change, and slow titration is the best protection against nausea and vomiting. If a dose is rough, the standard move is to stay at the current level longer rather than push up. Our retatrutide week-by-week and dosage chart pages cover titration scenarios in more depth.
Side effects in the first month and when to seek help
In the first month, the most common complaints are gastrointestinal: nausea, vomiting, diarrhea, constipation, reduced appetite, and sometimes burping or reflux. In the trial these effects were mostly mild to moderate and tended to ease as the body adjusted (Jastreboff et al., NEJM 2023). Increased heart rate has also been observed in this class.
Practical, low-risk ways to manage the everyday version of these symptoms include eating smaller meals, stopping before you feel full, avoiding greasy or very rich food, staying hydrated, and not rushing your dose increases. If nausea is significant, holding your current dose longer (rather than going up) is usually wiser than powering through. Our retatrutide side effects guide goes through each symptom in detail.
Some symptoms are not "wait and see." Treat the following as a triage list and seek medical care promptly.
| Warning sign | Why it matters |
|---|---|
| Severe, persistent abdominal pain, especially radiating to the back, with vomiting | Possible pancreatitis (FDA Zepbound label) |
| Pain in the upper right abdomen, fever, yellowing of skin or eyes | Possible gallbladder problem (DailyMed: Zepbound) |
| Shakiness, sweating, confusion, fast heartbeat (especially if on insulin or a sulfonylurea) | Low blood sugar (FDA Zepbound label) |
| Swelling of the face, lips, or throat, trouble breathing, hives | Serious allergic reaction (call emergency services) |
| Inability to keep fluids down, signs of dehydration, decreased urination | Risk of dehydration and kidney injury (FDA Zepbound label) |
| A lump in the neck, hoarseness, trouble swallowing | Reason to evaluate the thyroid (FDA Zepbound label) |
When in doubt, contact a clinician. The fact that you sourced the product yourself does not change the medicine: these warnings apply to the drug class.
What to expect week by week
Set realistic expectations. The dramatic averages from the trial happened over a full year at high doses, not in the first month. Here is a broad, illustrative arc based on how this drug class behaves.
| Time frame | What people often notice |
|---|---|
| Weeks 1 to 4 | Reduced appetite and earlier fullness; little or no scale change yet; gut side effects most likely now |
| Weeks 4 to 8 | More consistent appetite control; first steady weight changes as the dose builds |
| Weeks 8 to 12 | More noticeable, gradual weight loss; food cravings often quieter |
| Months 3 to 6 | The largest, steadiest losses for most people as the dose increases under guidance |
| Months 6 to 12 | Results continue to accumulate; the trial's 24.2% average came at week 48 (Jastreboff et al., NEJM 2023) |
Individual results vary widely, and a slower start is normal. Appetite suppression usually shows up before meaningful scale movement. For a granular breakdown, see our retatrutide week-by-week timeline.
Storage, handling, and common beginner mistakes
Lyophilized retatrutide powder is generally kept refrigerated and protected from light before mixing. Once reconstituted, it should be refrigerated and used within a limited window, and never frozen. Always inspect the solution before drawing: it should be clear and free of particles, and you should discard it if it looks cloudy or discolored. Our retatrutide storage guide covers temperatures, travel, and shelf life in detail.
The most common beginner mistakes are worth naming directly:
- Getting the reconstitution math wrong, which leads to under- or overdosing. Verify your concentration and your unit conversion before the first shot.
- Shaking the vial, which can damage the peptide. Swirl gently instead.
- Reusing needles or skipping swabbing, which raises infection risk. Single-use, every time.
- Titrating up too fast because results feel slow, which is the fastest route to severe nausea and vomiting.
- Injecting the same spot every week, causing lumps and uneven absorption. Rotate.
- Forgetting this is unregulated material. A research vial has no guarantee of what is actually in it, which is exactly why clinician oversight and the warning-sign list above matter so much (FDA).
Frequently Asked Questions
Is retatrutide FDA-approved?
No. Retatrutide is investigational and is not approved by the FDA for any use. It is still in clinical trials, and any version sold online as research or compounded material is unregulated, with no guarantee of its identity, purity, dose, or sterility (FDA).
How much weight could a beginner expect to lose?
It varies a great deal. In the Phase 2 trial, the average loss at the highest 12 mg dose was about 17.5% of body weight at week 24 and 24.2% at week 48 (Jastreboff et al., NEJM 2023). Beginners on lower, conservative doses, and over shorter time frames, should expect more modest, gradual results.
What is the best starting dose for a beginner?
There is no official starting dose because the drug is not approved. The trial showed that starting lower (2 mg rather than 4 mg) reduced side effects (Jastreboff et al., NEJM 2023), and the broader principle for this class is to start low and titrate slowly under a clinician's guidance. The schedule in this article is illustrative only.
Why do I have to mix it myself?
Retatrutide typically ships as a freeze-dried powder for stability, so it must be reconstituted with bacteriostatic water before it can be measured and injected. Getting this step and the unit math right is essential, which is why we recommend the full how to reconstitute retatrutide guide before your first vial.
What should make me stop and call a doctor right away?
Severe abdominal pain (possible pancreatitis), signs of an allergic reaction such as facial or throat swelling, symptoms of low blood sugar, persistent vomiting with dehydration, or a new neck lump all warrant prompt medical attention (FDA Zepbound label). When unsure, contact a clinician rather than waiting.
Can I take retatrutide if I am pregnant or breastfeeding?
No. This drug class is not recommended during pregnancy or breastfeeding, and the combination of reduced food intake and rapid weight loss can be harmful to a developing baby (DailyMed: Zepbound). If you could become pregnant, discuss contraception and timing with your clinician before starting anything.